TACI Gene (TNFRSF13B)

Gene Overview

Property	Value
Gene Symbol	TNFRSF13B
Full Name	TNF Receptor Superfamily Member 13B
Alternative Names	TACI, CD269
Chromosomal Location	17p11.2
NCBI Gene ID	9517
OMIM	604715
Ensembl ID	ENSG00000165502
UniProt ID	O14836
Gene Family	TNF receptor superfamily
Associated Diseases	ALS, CVID, Autoimmune Encephalitis, MS

Introduction

TACI (Transmembrane Activator and Calcium Modulator and Cyclophilin Ligand Interactor, or TNFRSF13B) is a critical member of the TNF receptor superfamily that plays essential roles in B cell function, immunoglobulin class switching, and immune system regulation. Encoded by the TNFRSF13B gene on chromosome 17p11.2, TACI is expressed primarily on B cells, particularly on marginal zone B cells, class-switched memory B cells, and plasma cells. The receptor binds two ligands, BAFF (B cell Activating Factor, also known as TNFSF13B) and APRIL (A Proliferation-Inducing Ligand, also known as TNFSF13), which are critical for B cell survival, maturation, and antibody production.

While TACI has been studied extensively in the context of humoral immunity and autoimmune diseases, emerging evidence suggests important roles in neuroinflammation and neurodegenerative diseases. The receptor is expressed in the central nervous system (CNS) by various cell types, including certain glial cells and possibly neurons, where it may contribute to B cell-mediated neuroinflammatory processes. This has implications for diseases such as multiple sclerosis (MS), autoimmune encephalitis, and potentially Alzheimer’s disease (AD) and Parkinson’s disease (PD).

Molecular Biology and Structure

The TNFRSF13B gene spans approximately 40 kilobases and consists of multiple exons encoding the TACI protein. Alternative splicing produces multiple isoforms, including a full-length membrane-bound form and soluble variants. The TACI protein is a type I transmembrane protein with the following structural features:

Extracellular Domain: The extracellular region contains multiple cysteine-rich domains (CRDs) characteristic of TNF receptor family members. These CRDs mediate ligand binding and interactions with BAFF and APRIL. The affinity for BAFF is moderate, while binding to APRIL requires higher concentrations. TACI can form both homomultimers and heteromultimers with other receptors.

Transmembrane Domain: A single pass transmembrane helix anchors the receptor in the cell membrane.

Cytoplasmic Domain: The intracellular region contains a “TRAF-binding motif” that allows recruitment of TRAF (TNF Receptor-Associated Factor) proteins, particularly TRAF2 and TRAF5, which mediate downstream signaling pathways.

The cytoplasmic domain also contains a “B cell linker” (BLINK) domain that interacts with proteins involved in B cell receptor signaling, linking TACI activation to calcium signaling and downstream transcriptional activation.

Signaling Pathways

TACI activates multiple intracellular signaling cascades upon ligand binding:

NF-κB Pathway

TACI engagement leads to activation of both canonical and non-canonical NF-κB pathways:

• Canonical NF-κB: TRAF2/5 recruitment activates the IKK complex, leading to IκB degradation and NF-κB nuclear translocation. This induces expression of survival genes, including Bcl-2 family proteins and NF-κB target genes.

• Non-canonical NF-κB: TACI signaling activates NF-κB-inducing kinase (NIK), which phosphorylates IKKα, leading to p100 processing to p52 and RelB activation. This pathway is particularly important for plasma cell survival.

MAPK Pathways

TACI activates:

• ERK pathway: Promotes cell proliferation and survival

• p38 pathway: Involved in stress responses and cytokine production

• JNK pathway: Modulates cellular stress responses

Calcium Signaling

TACI name derives from its ability to modulate calcium signaling in B cells. The receptor interacts with calcium-modulating cyclophilin ligand (CAML), affecting calcium influx and downstream signaling events important for B cell activation and antibody production.

mTOR Pathway

Recent evidence indicates TACI activates the mTOR (mammalian target of rapamycin) pathway, which is important for plasma cell differentiation and immunoglobulin production.

Expression and Cellular Distribution

Immune System Expression

TACI is primarily expressed in the B cell compartment:

• Marginal zone B cells: High expression in this specialized B cell population

• Class-switched memory B cells: Moderate expression

• Plasma cells: High expression, important for antibody secretion

• Activated B cells: Upregulated upon B cell receptor engagement

TACI expression is dynamic during B cell development and activation, regulated by factors including BAFF levels, B cell receptor signaling, and cytokines.

Central Nervous System Expression

In the CNS, TACI expression is more limited but has been documented:

• Microglia: Some subsets express TACI, particularly under inflammatory conditions

• Astrocytes: Limited expression reported

• Neurons: Some neuronal populations may express TACI, though this remains under investigation

• B cells: Infiltrating B cells in neuroinflammatory conditions express TACI

The CNS expression of TACI is upregulated in certain neuroinflammatory conditions, suggesting a role in B cell-mediated neuroinflammation.

Role in B Cell Function and Humoral Immunity

B Cell Survival and Maturation

BAFF and APRIL binding to TACI provides critical survival signals for B cells, particularly for transitional B cells and marginal zone B cells. TACI signaling upregulates anti-apoptotic proteins (Bcl-2, Bcl-xL) and promotes B cell maturation.

Class Switch Recombination

TACI is a key driver of immunoglobulin class switching from IgM to IgG, IgA, and IgE isotypes. This function is mediated through both BAFF and APRIL signaling and is critical for generating high-affinity antibodies with effector functions.

Plasma Cell Differentiation

TACI signaling promotes plasma cell differentiation and supports antibody secretion. The receptor helps plasma cells survive in the bone marrow microenvironment, which is essential for long-term humoral immunity.

T Cell-Independent Antibody Responses

TACI is particularly important for T cell-independent (TI) antibody responses, which are critical for defense against encapsulated bacteria and blood-borne antigens. TI antigens can stimulate B cells without T cell help, and TACI signaling enhances IgM and IgG production in this context.

Disease Associations

Common Variable Immunodeficiency (CVID)

CVID is the most common symptomatic antibody deficiency in adults, characterized by low immunoglobulin levels and recurrent infections. Heterozygous TNFRSF13B mutations are found in approximately 5-10% of CVID patients, making this the most common genetic cause of CVID identified to date.

Pathogenic Mutations: The most common disease-causing mutations include:

• A181E: A cysteine-to-arginine mutation in the extracellular domain

• C104R: A missense mutation affecting ligand binding

• P334A: A proline-to-alanine mutation in the intracellular domain

• Frameshift and nonsense mutations: Leading to truncated non-functional proteins

Mechanism: TACI mutations cause disease through both haploinsufficiency (reduced protein levels) and dominant-negative effects (mutant proteins interfere with wild-type function). The result is impaired B cell survival, reduced class switching, and defective antibody production.

Phenotype: CVID patients with TNFRSF13B mutations often present with:

• Recurrent sinopulmonary infections

• Autoimmune manifestations (autoimmune cytopenias, autoimmune hepatitis)

• Enteropathy

• Granulomatous disease

• Increased risk of lymphoma

Autoimmune Encephalitis

Autoimmune encephalitis (AE) is a group of disorders characterized by autoantibodies against neuronal antigens, leading to inflammation and dysfunction of the brain. TACI may play a role in the survival and function of autoantibody-producing B cells in the CNS.

Role: TACI expression on B cells within the CNS may support the survival of autoreactive B cell clones and the production of pathogenic autoantibodies. BAFF is elevated in the CSF of some AE patients, potentially creating a microenvironment that promotes autoantibody production.

Therapeutic Implications: B cell-depleting therapies (rituximab) and BAFF-targeting approaches may be beneficial in some forms of autoimmune encephalitis.

Amyotrophic Lateral Sclerosis (ALS)

ALS is a fatal neurodegenerative disease characterized by progressive loss of upper and lower motor neurons. Neuroinflammation, involving both innate and adaptive immune responses, is a key pathological feature.

Evidence for TACI involvement:

• B cells and plasma cells are present in ALS spinal cord lesions

• BAFF levels are elevated in ALS CSF and血清

• TACI is expressed on some immune cells in ALS tissue

• Autoantibodies have been detected in some ALS patients

Potential mechanisms: TACI may contribute to ALS through:

• B cell-mediated autoimmunity

• Production of autoantibodies against neuronal antigens

• Cytokine secretion by TACI-expressing immune cells

• Promotion of neuroinflammation through B cell interactions

Multiple Sclerosis (MS)

MS is an autoimmune demyelinating disease of the CNS with prominent B cell and antibody involvement.

Evidence for TACI involvement:

• B cells, plasma cells, and antibodies are prominent in MS lesions

• BAFF is elevated in MS CSF and brain tissue

• Oligoclonal bands (antibodies) in CSF are a diagnostic hallmark

• TACI is expressed on B cells in MS lesions

Potential mechanisms: TACI signaling may:

• Support survival of autoantibody-producing B cells in the CNS

• Promote class switching and affinity maturation of intrathecal antibodies

• Contribute to B cell-mediated demyelination

Alzheimer’s Disease and Parkinson’s Disease

Emerging evidence suggests roles for B cells and BAFF/TACI signaling in AD and PD:

• BAFF is elevated in AD and PD brains

• B cells and antibodies are found in AD and PD brains

• Autoantibodies are common in both diseases

• TACI may support neurotoxic B cell responses

Therapeutic Implications

Targeting TACI and BAFF Pathways

Several therapeutic strategies targeting the BAFF/TACI axis are in development or clinical use:

BAFF inhibitors:

• Belimumab: An anti-BAFF monoclonal antibody approved for systemic lupus erythematosus (SLE)

• Tabalumab: Another anti-BAFF antibody tested in SLE and other autoimmune diseases

TACI-Fc fusion proteins:

• Atacicept: A TACI-Fc fusion protein that binds both BAFF and APRIL, blocking their interaction with TACI and other receptors. Tested in MS, SLE, and other autoimmune diseases.

B cell depletion:

• Rituximab: Anti-CD20 monoclonal antibody depletes B cells, indirectly affecting TACI-expressing cells

• Ocrelizumab: Humanized anti-CD20 approved for MS

Clinical Trial Results

Clinical trials targeting BAFF/TACI pathways have shown:

• Belimumab: Effective in SLE but not tested in neuroinflammatory diseases

• Atacicept: Mixed results in MS; showed some benefit in optic neuritis but not in broader MS

• Rituximab: Effective in some forms of autoimmune encephalitis and MS

Cross-Linking and Related Pages

• BAFF (TNFSF13B) Gene

• BAFFR (TNFRSF13C) Gene

• B Cells

• NF-κB Signaling

• Neuroinflammation

• Autoimmune Encephalitis

• Multiple Sclerosis

• Amyotrophic Lateral Sclerosis

• Common Variable Immunodeficiency

See Also

• TNF Receptor Superfamily

• B Cell Development

• Antibody-Mediated Immunity

• Cytokine Signaling

• BAFF Signaling

External Links

• NCBI Gene - TNFRSF13B

• UniProt - O14836

• Ensembl - TNFRSF13B

• GeneCards - TNFRSF13B

• OMIM - TNFRSF13B